CYT-0851 Phase 1 Dose Escalation Results Show Early Clinical

- CYT-0851 has demonstrated broad clinical activity and a generally well tolerated safety profile in a heavily pretreated population of patients - Dur

Related Keywords

Illinois , United States , Chicago , American , Markus Renschler , Ryanc Lynch , Fred Hutchinson Cancer Center , Exchange Commission , Linkedin , American Society Of Clinical Oncology , Twitter , Cyteir Therapeutics Inc , Advanced Solid , Clinical Oncology , Chief Executive Officer , Assistant Professor , Action Insights Have Potential , Additional Tumor , Ongoing Phase , Expansion Cohorts , Study Expected , Cyteir Therapeutics , Annual Report ,